AMDC-USR

Phase 3Biologic

CCook MyoSite

AMDC-USR is one of 22 biologic programs targeting Stress urinary incontinence. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stress Urinary IncontinenceActive, not recruiting

Stress Urinary IncontinencePhase 3

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Stress Urinary Incontinence

#DrugCompanyPhaseTrials

Cymbalta

Alnylam Pharmaceuticals

Phase 3

10 2

Tofranil

Sanofi

Phase 3

2 3

Quietus

Merck & Co.

Phase 3

1 4

Foundayo

Eli Lilly

Phase 3

—5

Liposomal Bupivacaine

TTLC Biopharmaceuticals, Inc.

Approved

1 6

Duloxetine HCL

Eli Lilly

Approved

1 7

Toviaz

Pfizer

Phase 2

1 8

Platelet Rich Plasma

ZZagazig University

Phase 3

1 9

Depo-Testosterone

AAzurity Pharmaceuticals

Phase 2

1 10

Platelet Rich Fibrin

GGovernment Dental College and Research Institute, Bangalore

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

Post-Surgical

NCT03104517

Clinical

Trials by Indication[1]

Female1 trial

Japanese Bridging Study of Autologous Muscle Derived Cells Compared to Placebo for Female Urinary Sphincter Repair(JPN1)

Withdrawn·CCook MyoSite·Phase 3·NCT03997318

Stress urinary incontinence1 trial

Autologous Muscle Derived Cells Female Stress Urinary Incontinence Clinical Study

Completed·CCook MyoSite·Phase 3·NCT01382602·150 enrolled

Post-surgical1 trial

Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence

Active, not recruiting·CCook MyoSite·Phase 3·NCT03104517·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for AMDC-USR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AMDC-USR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AMDC-USR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cook MyoSite company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: CCook MyoSite

AMDC-USR

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Female1 trial

Stress urinary incontinence1 trial

Post-surgical1 trial

References

Drug Info

Quick Facts

Related News